Redesigning Heparin
Author:
- Robert D. RosenbergRRRobert D. Rosenberg
- 1 March 2001
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 344 (9) , 673-675
Abstract
The anticoagulant mechanism of heparin was obscure until 1973,1 when it was found that heparin enhances by as much as 1000 times the ability of the plasma protein antithrombin to form complexes with thrombin, factor Xa, and factor IXa, thereby inhibiting their activity and acting as an anticoagulant. Three years later, Lam et al. showed that only a small fraction of heparin binds to purified antithrombin, yet this fraction possesses virtually all of the anticoagulant activity of heparin.2 The region responsible for the anticoagulant activity of heparin has a unique oligosaccharide structure — the antithrombin-binding domain. Lindahl et al. made . . .Keywords
This publication has 6 references indexed in Scilit:
- A Synthetic Pentasaccharide for the Prevention of Deep-Vein Thrombosis after Total Hip ReplacementNew England Journal of Medicine, 2001
- A Novel Role for 3-O-Sulfated Heparan Sulfate in Herpes Simplex Virus 1 EntryCell, 1999
- Vascular-Bed–Specific Hemostasis and Hypercoagulable StatesNew England Journal of Medicine, 1999
- Contribution of monosaccharide residues in heparin binding to antithrombin IIIBiochemistry, 1985
- Total synthesis of a heparin pentasaccharide fragment having high affinity for antithrombin IIICarbohydrate Research, 1984
- The separation of active and inactive forms of heparinBiochemical and Biophysical Research Communications, 1976